Free tool
Rare disease stocks
We cover 34 companies grouped under the Rare disease theme. The median market value in the group is $3.55B. Across the group, the median move over the past trading day is +1.58%. 84% of the 32 with a 200-day average trade above it. Price change over the past year runs from +15.1% to +265.0% across the middle 80 percent of the group, with a median of +78.0%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
34 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc. | $84.86 | +1.20% | +81.60% | +182.02% |
| IMVT | Immunovant, Inc. | $43.50 | +8.51% | +67.89% | +192.14% |
| RYTM | Rhythm Pharmaceuticals, Inc. | $113.35 | +6.80% | +7.94% | +14.26% |
| SRRK | Scholar Rock Holding Corporation | $58.25 | +19.05% | +36.10% | +74.77% |
| ORKA | Oruka Therapeutics, Inc. | $101.82 | +12.88% | +260.17% | +601.72% |
| LQDA | Liquidia Corporation | $70.49 | −16.50% | +124.49% | +168.53% |
| KNSA | Kiniksa Pharmaceuticals International, plc | $80.20 | +26.23% | +90.93% | +142.74% |
| PTCT | PTC Therapeutics, Inc. Common Stock | $73.47 | −3.07% | −4.26% | +49.03% |
| DNTH | Dianthus Therapeutics, Inc. | $112.11 | +7.29% | +182.54% | +378.90% |
| TVTX | Travere Therapeutics, Inc. | $67.01 | +18.23% | +69.56% | +288.91% |
| MIRM | Mirum Pharmaceuticals, Inc. | $98.08 | −14.12% | +25.63% | +36.58% |
| GRFS | Grifols, S.A. | $8.09 | +4.39% | −12.45% | −17.62% |
| DYN | Dyne Therapeutics, Inc. | $26.34 | +2.77% | +42.38% | +102.62% |
| EWTX | Edgewise Therapeutics, Inc. | $44.21 | +6.27% | +86.15% | +209.16% |
| AMLX | Amylyx Pharmaceuticals, Inc. | $37.46 | +92.20% | +228.02% | +340.71% |
| MANE | Veradermics, Incorporated | $102.35 | −8.14% | +171.13% | +171.13% |
| CPRX | Catalyst Pharmaceuticals Inc | $31.49 | 0.00% | +36.03% | +52.72% |
| CLDX | Celldex Therapeutics, Inc. | $41.22 | +15.62% | +52.61% | +87.96% |
| IRON | Disc Medicine, Inc. | $82.41 | +10.45% | +4.20% | +38.71% |
| ARQT | Arcutis Biotherapeutics, Inc. | $24.86 | −10.70% | −14.28% | +58.44% |
| VRDN | Viridian Therapeutics, Inc. | $24.18 | +22.74% | −21.19% | +30.21% |
| PHVS | Pharvaris N.V. | $37.31 | +9.83% | +40.90% | +57.76% |
| RARE | Ultragenyx Pharmaceutical Inc. | $26.46 | −1.60% | +12.12% | −9.60% |
| TRVI | Trevi Therapeutics, Inc. | $17.95 | −0.94% | +50.97% | +146.57% |
| VERA | Vera Therapeutics, Inc. | $35.28 | +0.28% | −27.44% | +65.32% |
| NKTR | Nektar Therapeutics | $74.96 | +5.06% | +72.64% | +176.20% |
| BCRX | BioCryst Pharmaceuticals, Inc. | $9.83 | +2.61% | +31.07% | +17.16% |
| MLYS | Mineralys Therapeutics, Inc. | $26.34 | −3.20% | −26.24% | +78.70% |
| COAG | Hemab Therapeutics Holdings, Inc. | $49.65 | −1.47% | +46.03% | +46.03% |
| AUPH | Aurinia Pharmaceuticals Inc. | $16.75 | +10.05% | +9.12% | +38.03% |
| ZBIO | Zenas BioPharma, Inc. | $33.77 | +2.89% | −2.12% | +103.93% |
| STOK | Stoke Therapeutics, Inc. | $33.46 | +14.16% | +8.28% | +77.32% |
| ADMA | ADMA Biologics, Inc. | $9.72 | +14.62% | −45.64% | −42.86% |
| PVLA | Palvella Therapeutics, Inc. | $148.24 | +4.56% | +47.83% | +195.71% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.